BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors

Kinase inhibitors are accepted treatment for metastatic melanomas that harbor specific driver mutations in BRAF or KIT, but only 40% to 50% of cases are positive. To uncover other potential targetable mutations, we conducted whole-genome sequencing of a highly aggressive BRAF (V600) and KIT (W557, V...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer discovery 2012-09, Vol.2 (9), p.791-797
Hauptverfasser:	Dahlman, Kimberly Brown, Xia, Junfeng, Hutchinson, Katherine, Ng, Charles, Hucks, Donald, Jia, Peilin, Atefi, Mohammad, Su, Zengliu, Branch, Suzanne, Lyle, Pamela L, Hicks, Donna J, Bozon, Viviana, Glaspy, John A, Rosen, Neal, Solit, David B, Netterville, James L, Vnencak-Jones, Cindy L, Sosman, Jeffrey A, Ribas, Antoni, Zhao, Zhongming, Pao, William
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Cell Line, Tumor Genome, Human Humans Male MAP Kinase Kinase Kinases - antagonists & inhibitors MAP Kinase Kinase Kinases - genetics MAP Kinase Kinase Kinases - metabolism MAP Kinase Signaling System - drug effects Melanoma - drug therapy Melanoma - enzymology Melanoma - genetics Melanoma - pathology Mutation Protein Kinase Inhibitors - therapeutic use Proto-Oncogene Proteins B-raf - genetics Pyridones - therapeutic use Pyrimidinones - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!